熊錫山的個人首頁

　熊錫山，男，主治醫(yī)師，講師。曾師從中華醫(yī)學(xué)會腎臟病分會副主任委員、上海市腎臟病分會主任委員梅長林教授，2008年6月底獲第二軍醫(yī)大學(xué)腎臟病學(xué)博士學(xué)位，畢業(yè)后分配至軍事醫(yī)學(xué)科學(xué)院附屬醫(yī)院腎內(nèi)科，現(xiàn)職稱是主治醫(yī)師。 曾參與完成了多項科研課題： 　一、新型酪氨酸激酶抑制劑的研發(fā)和治療多囊腎病的實驗研究 ( 國家科技部863 項目編號:2002AA2Z3130 金額300萬); 　二、PPARγ激動劑的研發(fā)及治療多囊腎病實驗研究( 國家科技部863 項目編號: 2007AA02Z3Z1 金額50萬)。 　以第一作者身份共發(fā)表SCI收錄論著5篇，以共同第一作者身份發(fā)表SCI收錄論著1篇，以其他作者身份發(fā)表SCI收錄論著5篇。獲得專利2項，多年從事腎臟病基礎(chǔ)及臨床研究，對各種常見腎臟疾病、急慢性腎功能不全、血液凈化、多囊腎病的臨床救治，經(jīng)驗豐富。 目前已發(fā)表的文章: 　1. Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents. Xiong Xishan, Wang L, Ye Y, Fu L, Chen M, Wang Q, Liu M, Tang J, Dai B, Shen J, Mei C. Invest New Drugs. 2009 Jun 17. [Epub ahead of print] 2. B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest. Xiong Xishan, Zhang Y, Gao X, Dong Z, Li L, Ji C, Fu L, Luo X, Liu H, Mei C. Invest New Drugs. 2010 Feb;28(1):26-34. Epub 2009 Jan 13. 3. Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines. Xiong Xishan, Liu H, Fu L, Li L, Li J, Luo X, Mei C. Chemotherapy. 2008;54(6):463-74. Epub 2008 Oct 2. 4. Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines. Xiong Xishan, Ye Y, Fu L, Dai B, Liu J, Jia J, Tang J, Li L, Wang L, Shen J, Mei C. Invest New Drugs. 2009 Jun;27(3):223-32. Epub 2008 Aug 13. 5. Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo. Xiong Xishan, Fu L, Wang L, Cai H, Li L, Jiang H, Duan W, Mei C. Invest New Drugs. 2009 Feb;27(1):1-11. Epub 2008 May 21. 6. Antitumor efficacy of two novel non-thiazolidinedione compounds as peroxisome proliferator-activated receptor-gamma agonists in human osteosarcoma cells in vitro. Fu L, Xiong Xishan, Wang L, Gao X, Ye Y, Jia J, Hu H, Li L, Shen J, Mei C. Chemotherapy. 2009;55(6):468-76. Epub 2009 Dec 9. 7. Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease. Zhang T, Wang L, Xiong Xishan, Mao Z, Wang L, Mei C. Biol Res. 2009;42(4):437-44. Epub 2010 Jan 29. 8. DH9, a novel PPARgamma agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of beta-catenin signaling. Liu M, Fu L, Liu C, Xiong Xishan, Gao X, Xiao M, Cai H, Hu H, Wang X, Mei C. Invest New Drugs. 2009 Sep 16. [Epub ahead of print] 9. Identification of phosphoproteins in kidney tissues from patients with autosomal dominant polycystic kidney disease. Yawei Liu, Bing Dai, Changlin Mei, Yan Zhang, Xiong Xishan, Richard Sandford. Proteomics - Clinical Applications. Volume 2 Issue 7-8, Pages 1153 - 1166 10. Design, synthesis and antitumor evaluation of a new series of N-substituted-thiourea derivatives.. Li J, Tan JZ, Chen LL, Zhang J, Shen X, Mei CL, Fu LL, Lin LP, Ding J, Xiong B, Xiong Xishan, Liu H, Luo XM, Jiang H